Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Color Matters in Managing Hypertension
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Dr. A. Paul Chous Part 4, Diabetes Visual Function
HOMERUN SLIDES — Great Clinical Presentation Highlights
Pharmacologic Management of Type 2 Diabetes Part 4
CLINICAL GEMS — The Best from Diabetes Texts
MOST POPULAR ARTICLES OF THE MONTH
#1 Victoza LEADER Trial Top-Line Results Announced
#2 Blood-Pressure Drug Could Be A Possible Type 1 Diabetes Cure
#3 Misuse of New Insulin Strengths
Editor's Note
This past week it seems that the genomic testing company 23&ME has been on an advertising blitz. Maybe they feel that Independence Day is a great time for people to think about their heritage. It was interesting that after one of their commercials, there was one from a large cancer treatment center talking about how genetics can play a big role in selecting the right treatment for certain cancers, and how the future of this type of testing will be used more and more for treatment choices. This week our Disaster Avoided looks at how genetics plays a role in the treatment of hypertension, and how people of color sometimes need a different medication choice.
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
African American male, 63 years of age, type 2 diabetes, hypertension, strong family history of type 2 diabetes, hypertension and stroke. A1C is 6.7%. Blood pressure 160/96 HR 88, despite being on ACE-I and Beta Blocker.
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
In part 4 of this Exclusive Interview, Dr. Chous discusses his findings during a clinical trial of a multi-component supplement used to intervene in the development of diabetic retinopathy and improve visual function.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, part 4 of the Canadian Diabetes Association’s specific recommendations for patient-centered diabetes care.
CLINICAL GEMS — The Best from Diabetes Texts
In pancreatic beta cells, glucose metabolism is essential for the regulation of insulin secretion. Glucose is taken up by glucose transporters and metabolized to generate adenosine triphosphate (ATP), which is the main driver of glucose-induced insulin secretion (GIIS). Increased cytosolic ATP causes closure of ATP-sensitive K+ (KATP) channels, depolarizing the plasma membrane, leading to the opening of voltage-dependent Ca2+ channels (VDCCs), which allows Ca2+ influx. The resultant rise in intracellular Ca2+ concentration ([Ca2+]i) induces exocytosis of insulin granules in the triggering pathway of insulin secretion. In addition, other signals generated by glucose amplify insulin secretion. Lipid metabolism is also involved in GIIS by interacting with glucose metabolism.
MOST POPULAR ARTICLES OF THE MONTH
Victoza LEADER trial of 9,000 adults with type 2 diabetes found that drug significantly reduced the risk of heart attack or stroke.
A common blood pressure drug is showing new promise to help treat and cure type 1 diabetes.
We certainly have important education to accomplish with patients and health professionals regarding the new higher concentration insulin products that are available only in a pen, including U-300 TOUJEO (insulin glargine), U-200 TRESIBA (insulin degludec), and U-200 HUMALOG (insulin lispro). U-500 insulin is also available in a pen (HUMULIN), although vials remain on the market. Patients may not understand proper dosing and dose measurement with these higher concentrations of insulin products.